Accelerate Your BPH Patients’ Path to Better Living

For decades, treating BPH has meant making a hard choice between medications, which may have bothersome side effects,8 or surgical treatment, with risk of sexual dysfunction.10

Now you can change a patient’s journey with confidence. The UroLift™ System can help men get off BPH medications and avoid major surgery.2 This straightforward procedure provides rapid symptom relief and recovery3,4 and preserves sexual function.*2

AUA BPH Guideline Recognize the Need for Earlier Intervention

“Since many men discontinue medical therapy, yet proportionately few seek surgery, there is a large clinical need for an effective treatment that is less invasive than surgery. With this treatment class, perhaps a significant portion of men with BOO [bladder outlet obstruction] who have stopped medical therapy can be treated prior to impending bladder dysfunction.5”

The UroLift™ System is part of the standard of care for BPH treatment.5

Explore AUA Guideline 2021

What is UroLift™?

Discover How UroLift Works

The UroLift™ System is the only leading enlarged prostate procedure that does not require heating, cutting, removal, or destruction of prostate tissue.3,10

Treatment with the UroLift™ System can be performed as a same-day outpatient procedure, including the office setting, under local anesthesia.4 It does not preclude future BPH treatments, should they be necessary.2

Safety

Risk profile better than reported for surgical procedures such as TURP3,8,9

Efficacy

Rapid symptom relief and recovery3,4 with no new, sustained erectile or ejaculatory dysfunction*2

Proven Durability

Proven to achieve sustained improvements in IPSS, QoL, and Qmax through 5 years2

Faster Recovery. Fewer Risks. Proven Outcomes.2,4,8,10

Review Clinical Results
Patient Experience

Lowest rate of complications at one year when compared to both minimally invasive and invasive procedures.**14

89%

of obstructive median lobe patients would recommend the procedure at 1 month11

Durable Results

Improvements in symptoms, urinary flow, and quality of life sustained through 5 years2 with a retreatment rate of 13.5% at 5 years.2,3

50%

improvement in quality of life sustained over a 5 year study2

Preservation of Sexual Function

The only leading BPH procedure shown not to cause new and lasting sexual dysfunction.*10,12

0%

ejaculatory and erectile dysfunction*2

The Right Solution for Many BPH Patients

The UroLift™ System provides consistent outcomes to a broad range of BPH patients.13

Prostate Indications for the UroLift™ System✝
Minimum prostate volume None
Maximum prostate volume 100 cc
Obstructive median lobe Yes

The UroLift™ System Real World Retrospective Registry demonstrates that patients outside of the norm seen in clinical trials can be treated safely and effectively.13

  • Younger patients
  • Patients in retention
  • Prostates <30cc
  • History of prostate cancer treatment
  • Diabetic patients

500,000

BPH patients have been treated with the UroLift™ System15

Download Brochure
Peer Perspectives

Learn about the latest clinical developments from your peers.
Become a UroLift Physician

Learn about our onboarding process and path to long-term success.
View Products

Learn about more about the UroLift™ System procedure and devices.

Talk to Your Patient About the UroLift® System Today

Patients who seek medical advice might not be fully aware of the treatment options available to them and will need appropriate information and time to make a decision. Providing materials explaining their options, that they can bring home to discuss with their loved ones will be beneficial.

Download Patient Info Booklet

Not all products shown on the website may be approved in all regulatory jurisdictions. Consult with your local Teleflex representative for details.
Consult the Instructions for Use (IFU) for more information.
The information contained on this website is intended only for health care professionals in Australia.

† Food and Drug Administration (FDA) patient criteria for the UroLift™ System
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study
**Procedural complications were defined as complications requiring a return procedure in the outpatient setting ≥1d post-procedure

References

1.

U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/ warranties, including accuracy or completeness.

2.

Roehrborn et al. Can J Urol 2017

3.

Roehrborn, J Urology 2013

4.

Shore, Can J Urol 2014

5.

AUA Guidelines 2021

6.

Flanigan, J Urol 1998

7.

Tubaro, Drugs Aging 2003

8.

Sonksen, Eur Urol 2015

9.

AUA BPH Guidelines 2003

10.

AUA BPH Guidelines 2003, 2020

11.

Rukstalis, Prostate Cancer Prostatic Dis 2018

12.

McVary, Urology 2019

13.

Eure, J Endourol 2019

14.

Kaplan, Prostate Cancer Prostatic Dis 2023

15.

Management estimate based on product sales as of June 2024. Data on file Teleflex Interventional Urology

Healthcare Professional Confirmation

The information on the page you are about to enter is intended for Healthcare Professionals only.
By clicking the box below, you confirm that you are a Healthcare Professional.

Continue